Cargando…
A multi-centre, double-blind, placebo-controlled, randomised trial of combination methotrexate and gefitinib versus methotrexate alone to treat tubal ectopic pregnancies (GEM3): trial protocol
BACKGROUND: Tubal ectopic pregnancy (tEP) is the most common life-threatening condition in gynaecology. Treatment options include surgery and medical management. Stable women with tEPs with pre-treatment serum human chorionic gonadotrophin (hCG) levels < 1000 IU/L respond well to outpatient medic...
Autores principales: | May, James, Duncan, Colin, Mol, Ben, Bhattacharya, Siladitya, Daniels, Jane, Middleton, Lee, Hewitt, Catherine, Coomarasamy, Arri, Jurkovic, Davor, Bourne, Tom, Bottomley, Cecilia, Peace-Gadsby, Alexandra, Doust, Ann, Tong, Stephen, Horne, Andrew W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247635/ https://www.ncbi.nlm.nih.gov/pubmed/30458863 http://dx.doi.org/10.1186/s13063-018-3008-6 |
Ejemplares similares
-
Phase II single arm open label multicentre clinical trial to evaluate the efficacy and side effects of a combination of gefitinib and methotrexate to treat tubal ectopic pregnancies (GEM II): study protocol
por: Horne, Andrew W, et al.
Publicado: (2013) -
Combination gefitinib and methotrexate treatment for non-tubal ectopic pregnancies: a case series
por: Horne, A.W., et al.
Publicado: (2014) -
Methotrexate vs expectant management for treatment of tubal ectopic pregnancy: An individual participant data meta‐analysis
por: Solangon, Sarah Annie, et al.
Publicado: (2023) -
Gefitinib and Methotrexate to Treat Ectopic Pregnancies with a Pre-Treatment Serum hCG 1000–10,000 IU/L: Phase II Open Label, Single Arm Multi-Centre Trial()
por: Skubisz, Monika M., et al.
Publicado: (2018) -
Subsequent pregnancy outcomes among women with tubal ectopic pregnancy treated with methotrexate
por: Mackenzie, Scott C, et al.
Publicado: (2023)